1. severe covid-19 having oxygen saturation (spo2) ≤ 93 % on room air at sea level or ratio of arterial oxygen partial pressure (pao2 in millimeters of mercury) to fractional inspired oxygen (fio2) \< 300, respiratory rate ≥ 30/min, heart rate ≥ 125/min 2. requires mechanical ventilation or anticipated impending need for mechanical ventilation 3. known allergies to any of the components used in the formulation of the interventions 4. have received an investigational intervention for sars-cov-2 prophylaxis within 30 days before dosing 5. have received treatment with a sars-cov-2 specific monoclonal antibody note: other protocol defined inclusion/exclusion criteria may apply.

1. severe covid-19 having oxygen saturation (spo2) ≤ 93 % on room air at sea level or ratio of arterial oxygen partial pressure (pao2 in millimeters of mercury) to fractional inspired oxygen (fio2) \< 300, respiratory rate ≥ 30/min, heart rate ≥ 125/min 2. requires mechanical ventilation or anticipated impending need for mechanical ventilation 3. known allergies to any of the components used in the formulation of the interventions 4. have received an investigational intervention for sars-cov-2 prophylaxis within 30 days before dosing 5. have received treatment with a sars-cov-2 specific monoclonal antibody note: other protocol defined inclusion/exclusion criteria may apply.

severe covid-19 having oxygen saturation (spo2) ≤ 93 % on room air at sea level or ratio of arterial oxygen partial pressure (pao2 in millimeters of mercury) to fractional inspired oxygen (fio2) < 300, respiratory rate ≥ 30/min, heart rate ≥ 125/min requires mechanical ventilation or anticipated impending need for mechanical ventilation known allergies to any of the components used in the formulation of the interventions have received an investigational intervention for sars-cov-2 prophylaxis within 30 days before dosing have received treatment with a sars-cov-2 specific monoclonal antibody note: other protocol defined inclusion/exclusion criteria may apply.

severe covid-19 having oxygen saturation (spo2) ≤ 93 % on room air at sea level or ratio of arterial oxygen partial pressure (pao2 in millimeters of mercury) to fractional inspired oxygen (fio2) < 300, respiratory rate ≥ 30/min, heart rate ≥ 125/min requires mechanical ventilation or anticipated impending need for mechanical ventilation known allergies to any of the components used in the formulation of the interventions have received an investigational intervention for sars-cov-2 prophylaxis within 30 days before dosing have received treatment with a sars-cov-2 specific monoclonal antibody note: other protocol defined inclusion/exclusion criteria may apply.

1. severe covid-19 having oxygen saturation (spo2) ≤ 93 % on room air at sea level or ratio of arterial oxygen partial pressure (pao2 in millimeters of mercury) to fractional inspired oxygen (fio2) < 300, respiratory rate ≥ 30/min, heart rate ≥ 125/min 2. requires mechanical ventilation or anticipated impending need for mechanical ventilation 3. known allergies to any of the components used in the formulation of the interventions 4. have received an investigational intervention for sars-cov-2 prophylaxis within 30 days before dosing 5. have received treatment with a sars-cov-2 specific monoclonal antibody note: other protocol defined inclusion/exclusion criteria may apply.

1. severe covid-19 having oxygen saturation (spo2) ≤ 93 % on room air at sea level or ratio of arterial oxygen partial pressure (pao2 in millimeters of mercury) to fractional inspired oxygen (fio2) < 300, respiratory rate ≥ 30/min, heart rate ≥ 125/min 2. requires mechanical ventilation or anticipated impending need for mechanical ventilation 3. known allergies to any of the components used in the formulation of the interventions 4. have received an investigational intervention for sars-cov-2 prophylaxis within 30 days before dosing 5. have received treatment with a sars-cov-2 specific monoclonal antibody note: other protocol defined inclusion/exclusion criteria may apply.